



## Silver State Scripts Board (SSSB) Made Changes to the Preferred Drug List (PDL) Effective October 10, 2024

The Silver State Scripts Board (SSSB) met on September 26, 2024 and voted to adopt the following changes to the Nevada Medicaid Preferred Drug List (PDL) effective October 10, 2024.

The complete PDL is posted on the [“Preferred Drug List”](#) webpage

Drug Class/Program	Changes
<b>Miscellaneous Heart Failure Agents</b>	<ul style="list-style-type: none"> <li>Ivabradine, the generic for Corlanor<sup>®</sup>, added as preferred</li> <li>Corlanor<sup>®</sup> moved from preferred to non-preferred, and defined as both the tab and soln</li> <li>Current preferred drug Entresto<sup>®</sup> defined as “Entresto<sup>®</sup> tab”</li> <li>New dosage form, Entresto<sup>®</sup> sprinkle cap, added as non-preferred</li> </ul>
<b>Phosphodiesterase 4 Inhibitors</b>	<ul style="list-style-type: none"> <li>Drug class adjusted from “Phosphodiesterase 4 Inhibitors” to “Phosphodiesterase 4 Inhibitors or Combination”</li> <li>Ohtuvayre<sup>™</sup> added as preferred</li> </ul>
<b>Erythropoiesis-Stimulating Agents</b>	<ul style="list-style-type: none"> <li>Vafseo<sup>®</sup> added as non-preferred</li> <li>Reblozyl<sup>®</sup> added as non-preferred</li> </ul>
<b>Movement Disorders</b>	<ul style="list-style-type: none"> <li>Current preferred drug Ingrezza<sup>®</sup> defined as “Ingrezza<sup>®</sup> cap”</li> <li>New dosage form, Ingrezza<sup>®</sup> sprinkle cap, added as preferred</li> <li>Austedo XR<sup>®</sup> titration pack moved from non-preferred to preferred</li> </ul>
<b>Targeted Immunomodulators</b>	<ul style="list-style-type: none"> <li>Adalimumab-aacf, adalimumab-aaty, adalimumab-adbm, adalimumab-ryvk, Abrilada<sup>®</sup>, and Simlandi<sup>®</sup> added as non-preferred</li> <li>Bimzelx<sup>®</sup> added as non-preferred</li> <li>Omvoh<sup>®</sup> added as non-preferred</li> <li>Taltz<sup>®</sup> moved from preferred to non-preferred</li> <li>Velsipity<sup>®</sup> added as non-preferred</li> </ul>

	<ul style="list-style-type: none"> <li>• Zeposia<sup>®</sup> added as non-preferred</li> </ul>
<b>Incretin Mimetics and Combinations</b>	<ul style="list-style-type: none"> <li>• Liraglutide, the generic for Victoza<sup>®</sup>, added as non-preferred</li> <li>• Adlyxin<sup>®</sup> removed from PDL due to product discontinuation</li> </ul>
<b>Dipeptidyl Peptidase-4 Inhibitors and Combinations with Metformin</b>	<ul style="list-style-type: none"> <li>• Kazano<sup>®</sup>, Nesina<sup>®</sup>, and Oseni<sup>®</sup> removed from PDL due to product discontinuation</li> </ul>
<b>Non-Ergot Dopamine Agonists</b>	<ul style="list-style-type: none"> <li>• Azilect<sup>®</sup> added as non-preferred</li> <li>• Kynmobi<sup>®</sup> removed from PDL due to product discontinuation</li> <li>• Pramipexole ER added as non-preferred</li> <li>• Mirapex ER<sup>®</sup> moved from preferred to non-preferred</li> <li>• Rasagiline added as non-preferred</li> </ul>
<b>Ophthalmic Quinolones</b>	<ul style="list-style-type: none"> <li>• Moxifloxacin (generic for Vigamox<sup>®</sup>) moved from non-preferred to preferred</li> <li>• Moxifloxacin (generic for Moxeza<sup>®</sup>) kept as non-preferred</li> <li>• Vigamox<sup>®</sup> moved from preferred to non-preferred</li> <li>• Ophthalmic levofloxacin removed from the PDL due to manufacturer no longer participating in the Medicaid Drug Rebate Program</li> <li>• Moxeza<sup>®</sup> removed from the PDL due to product discontinuation</li> </ul>
<b>Second-Generation Cephalosporins</b>	<ul style="list-style-type: none"> <li>• Cefaclor susp and ER tablet moved from preferred to non-preferred</li> <li>• Cefuroxime susp removed from PDL due to product discontinuation</li> </ul>
<b>Bisphosphonates</b>	<ul style="list-style-type: none"> <li>• Ibandronate tab moved from non-preferred to preferred</li> <li>• Risedronate (generic for Actonel<sup>®</sup>) added as preferred</li> <li>• Risedronate (generic for Atelvia<sup>®</sup>) added as non-preferred</li> <li>• Boniva<sup>®</sup> and etidronate (generic for Didronel<sup>®</sup>) removed from PDL due to product discontinuation</li> </ul>